SCHEMBL2582477

SCHEMBL2582477

Cc1ccc(-c2ccc3c(O)c(CNCC(=O)O)c(=O)n(C)c3n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.39
EGLN1 Q9GZT9 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TRPA1 O75762 1/20 0.35
PDE10A Q9Y233 1/20 0.35
KDM5B Q9UGL1 2/20 0.35
RAB9A P51151 1/20 0.34
TMIGD3 P0DMS9 1/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
TP53 P04637 3/20 0.33
MAPT P10636 3/20 0.33
RXFP1 Q9HBX9 3/20 0.33
PPARG P37231 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
NR2E3 Q9Y5X4 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
NCOA2 Q15596 1/20 0.33
NCOA1 Q15788 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2583691 0.89 HIF1A (0.42) EGLN1KDM5BTMIGD3ALDH1A1HIF1A
SCHEMBL2582383 0.85 EGLN1 (0.44) EGLN1KDM4EALDH1A1HPGDMAPT
SCHEMBL2582478 0.81 EGLN1 (0.56) EGLN1HIF1A
SCHEMBL2578322 0.81 ERCC1 (0.43) SMN1; SMN2RAB9AKDM4EALDH1A1HPGD
SCHEMBL2576947 0.72 EGLN1 (0.59) EGLN1KDM5BHIF1A
SCHEMBL2583694 0.70 HIF1A (0.63) EGLN1HIF1A
SCHEMBL12101602 0.66 HIF1A (0.53) EGLN1SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL337484 0.65 EGLN1 (0.68) EGLN1HIF1A
SCHEMBL2582034 0.63 HIF1A (0.48) EGLN1RAB9AKDM4EHIF1A
SCHEMBL2585467 0.63 EGLN1 (0.49) EGLN1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048892-B2 Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-11-01 US disclosed
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof EGLN3, EGLN2, HIF1AN GRM2 4418/4885EGLN1 5/4885SMN1; SMN2 4514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.